Bio Green Med Solution (BGMS) vs XTL Biopharmaceuticals (XTLB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Bio Green Med Solution is the larger company by market cap ($3.7 million vs $3.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BGMS | XTLB |
|---|---|---|
| Share price | $0.553 | $1.37 |
| Market cap | $3.66M | $3.37M |
| 1-day change | -9.48% | -5.84% |
| EPS (TTM) | $-3.78 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $451.00K |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-3.00M | $-1.03M |
| Gross margin | — | 0.67% |
| Operating margin | — | -481.60% |
| Net margin | — | -227.72% |
| 52-week high | $2.80 | $5.64 |
| 52-week low | $0.55 | $1.37 |
| Distance from 52-week high | -80.25% | -75.71% |
| Average volume | 76.12K | 6.58K |
| Shares outstanding | 6.62M | 2.46M |
| Employees | — | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bio Green Med Solution
BGMS stock →Bio Green Med Solution, Inc. engages in the distributing, trading, and installation of protective and fire safety materials and equipment, and fire protection and prevention systems.
Health Care · Biotechnology: Pharmaceutical Preparations
About XTL Biopharmaceuticals
XTLB stock →XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
BGMS vs XTLB FAQ
Which is bigger, Bio Green Med Solution or XTL Biopharmaceuticals?
Bio Green Med Solution (BGMS) is larger, with a market capitalization of $3.66M compared with $3.37M for XTL Biopharmaceuticals (XTLB).
Are Bio Green Med Solution and XTL Biopharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.